Hyperuricosuric Calcium Urolithiasis

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2018 Jan 26

PMID 29368300

Citations 12

Authors

Orson W Moe

Li Hao Richie Xu

Affiliations

Soon will be listed here.

Abstract

Hyperuricosuric calcium urolithiasis is a condition of mixed calcium oxalate stones characterized by hyperuricosuria either in isolation or in conjunction with other risk factors for calcium oxalate stones such as hypercalciuria, hyperoxaluria, and hypocitraturia. There are three proposed physicochemical models of pathogenesis where urate in its crystalline phase via heterogeneous nucleation, in its colloidal phase via removal of crystallization inhibitors, and in solution via precipitation crystallization, can all increase propensity to calcium oxalate precipitation. Regardless of the model, the phenomenologic observation of urate increasing calcium oxalate precipitation appears solid. Another supporting factor are retrospective data analysis and prospective trials showing uric acid lowering reduces stones events in hyperuricosuric calcium stone formers. Due to the heterogeneity of pathogenesis of calcium oxalate stones in the unselected stone-formers, association cannot be demonstrated between uric acid excretion rate and risk of kidney stone the general population. In calcium oxalate stoners with isolated hyperuricosuria or hyperuricosuria in combination with other calcium stone risks where treatment of these traditional risks fails to reduce stone formation, urate acid lowering should be cautiously attempted. More refinement of pathogenic models and prospective controlled trials in phenotypically defined subgroups of subjects with calcium oxalate urolithiasis will be informative.

Citing Articles

Effect of Body Mass Index on complications and success rates of percutaneous nephrolithotomy-A tertiary care hospital experience.

Iqbal N, Hasan A, Razzaq S, Rashid F Pak J Med Sci. 2022; 38(8):2112-2117.

PMID: 36415255 PMC: 9676566. DOI: 10.12669/pjms.38.8.3663.

Numerical characterization of astronaut CaOx renal stone incidence rates to quantify in-flight and post-flight relative risk.

Goodenow-Messman D, Gokoglu S, Kassemi M, Myers Jr J NPJ Microgravity. 2022; 8(1):2.

PMID: 35091560 PMC: 8799707. DOI: 10.1038/s41526-021-00187-z.

Association between hyperlipidemia and calcium oxalate lower urinary tract uroliths in dogs.

Paulin M, Dunn M, Vachon C, Beauchamp G, Conversy B J Vet Intern Med. 2021; 36(1):146-155.

PMID: 34854133 PMC: 8783332. DOI: 10.1111/jvim.16324.

The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis.

Tai C, Wu C, Lee K, Tseng T, Wang H, Chang F Clin Pharmacol Ther. 2021; 111(3):655-663.

PMID: 34719019 PMC: 9298734. DOI: 10.1002/cpt.2473.

Calcium oxalate urolithiasis in juvenile dogs.

Saver A, Lulich J, Van Buren S, Furrow E Vet Rec. 2021; 189(3):e141.

PMID: 34357620 PMC: 9159368. DOI: 10.1002/vetr.141.

References

KALLISTRATOS G, Timmermann A, FENNER O . [Influence of the salting-out effect on the formation of calcium oxalate crystals in human urine]. Naturwissenschaften. 1970; 57(4):198. DOI: 10.1007/BF00592988. View

Grover P, Ryall R . The effect of preincubation of seed crystals of uric acid and monosodium urate with undiluted human urine to induce precipitation of calcium oxalate in vitro : implications for urinary stone formation. Mol Med. 2002; 8(9):525-35. PMC: 2040018. View

Ettinger B, Tang A, Citron J, Livermore B, Williams T . Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986; 315(22):1386-9. DOI: 10.1056/NEJM198611273152204. View

Sechi L, Colussi G, Novello M, Uzzau A, Catena C . Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?. Horm Metab Res. 2015; 47(13):1000-6. DOI: 10.1055/s-0035-1565128. View

Rodgers A, Allie-Hamdulay S, Jackson G . Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol Dial Transplant. 2005; 21(2):361-9. DOI: 10.1093/ndt/gfi211. View

Coe F, LAWTON R, Goldstein R, Tembe V . Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med. 1975; 149(4):926-9. DOI: 10.3181/00379727-149-38928. View

Porter P . Colloidal properties of urates in relation to calculus formation. Res Vet Sci. 1966; 7(2):128-37. View

PRIEN E, Prien Jr E . Composition and structure of urinary stone. Am J Med. 1968; 45(5):654-72. DOI: 10.1016/0002-9343(68)90202-7. View

Egan B, Li J . Role of aldosterone blockade in resistant hypertension. Semin Nephrol. 2014; 34(3):273-84. DOI: 10.1016/j.semnephrol.2014.04.004. View

10.

Augustin A, Boker T, Blumenroder S, Lutz J, Spitznas M . Free radical scavenging and antioxidant activity of allopurinol and oxypurinol in experimental lens-induced uveitis. Invest Ophthalmol Vis Sci. 1994; 35(11):3897-904. View

11.

Pak C, Hayashi Y, Arnold L . Heterogeneous nucleation with urate, calcium phosphate and calcium oxalate. Proc Soc Exp Biol Med. 1976; 153(1):83-7. DOI: 10.3181/00379727-153-39485. View

12.

Pacher P, Nivorozhkin A, Szabo C . Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58(1):87-114. PMC: 2233605. DOI: 10.1124/pr.58.1.6. View

13.

Smith M, HUNT L, KING Jr J, Boyce W . Uricemia and urolithiasis. J Urol. 1969; 101(5):637-42. DOI: 10.1016/s0022-5347(17)62393-0. View

14.

Khan S . Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res. 2005; 33(5):349-57. DOI: 10.1007/s00240-005-0492-4. View

15.

Pak C, Barilla D, Holt K, Brinkley L, Tolentino R, Zerwekh J . Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Am J Med. 1978; 65(4):593-9. DOI: 10.1016/0002-9343(78)90846-x. View

16.

Klein A, Joh J, Rangan U, Wang D, Bulkley G . Allopurinol: discrimination of antioxidant from enzyme inhibitory activities. Free Radic Biol Med. 1996; 21(5):713-7. DOI: 10.1016/0891-5849(96)00158-x. View

17.

Coe F . Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med. 1977; 87(4):404-10. DOI: 10.7326/0003-4819-87-4-404. View

18.

Coe F, Raisen L . Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet. 1973; 1(7795):129-31. DOI: 10.1016/s0140-6736(73)90197-9. View

19.

Cicconi L, Lo-Coco F . Current management of newly diagnosed acute promyelocytic leukemia. Ann Oncol. 2016; 27(8):1474-81. DOI: 10.1093/annonc/mdw171. View

20.

Werness P, Brown C, Smith L, Finlayson B . EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol. 1985; 134(6):1242-4. DOI: 10.1016/s0022-5347(17)47703-2. View